Other Name(s): IL-17, IL-17A
Drug Target Analysis Report Drug Target Analysis Report Content

About the Target

IL-17A, also known as IL-17, plays critical roles in various immune responses and diseases. In the context of SARS-CoV-2 infection, IL-17A is found to be enriched, leading to a disproportionate immune response and recruitment of innate immune cells, which can result in complications such as ARDS, sepsis, and fibrosis [1]. Furthermore, deficiencies in the IL-17 response pathway can impair cellular responses to IL-17A/F and IL-17A/F production, leading to certain genetic disorders [2]. In psoriasis, IL-17 production by gammadelta T cells contributes to the development of the disease [3]. Additionally, IL-17A is implicated in bone erosion and bone formation in spondyloarthritis [4]. The role of IL-17A in signaling pathways and its interaction with other components, such as NEMO and TBK1/IKKepsilon, is also being studied [5].
Based on the given context information, here is a summary of key viewpoints related to IL-17A:

IL-17A plays a role in regulating inflammation induced by rhinovirus infections in the upper airways [6].
IL-17A can inhibit the expression of low-density lipoprotein receptor (LDL-R) and restrict the entry of rhinovirus into airway epithelial cells [6].
Rhinovirus has the ability to suppress the release of IL-17A, enabling it to evade the immune system [6].
IL-17A has both tumor-promoting and tumor-protective effects in cancer, with its effects attributed to various molecular signaling pathways and immune cell recruitment [7].
IL-17A is produced by different immune cell subsets, such as MAIT cells, gammadelta T cells, NKT cells, and ILC3s, and contributes to the pathogenesis of immune-mediated inflammatory diseases like psoriatic arthritis and psoriasis [8][9].
IL-17A induces the production of pro-inflammatory cytokines and drives disease progression in psoriatic skin lesions [9].
IL-17A is involved in the immune response to H. pylori infection, with Th1 and Th17 cells producing proinflammatory cytokines that recruit immune cells to the gastric mucosa [10].

Overall, IL-17A has diverse roles in regulating inflammation, immune responses, and disease progression in various contexts. Further research is needed to fully understand its mechanisms and potential therapeutic interventions.

Figure [1]

Figure [2]

Figure [3]

Figure [4]

Figure [5]

Figure [6]

Figure [7]

Figure [8]

Figure [9]

Figure [10]

Note: If you are interested in the full version of this target analysis report, or if you'd like to learn how our AI-powered BDE-Chem can design therapeutic molecules to interact with the IL17A target at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai.

More Common Targets

ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BECN1 | BRAF | BRCA1 | CAMP | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CD8A | CDH1 | CDKN1A | CDKN2A | CREB1 | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | EREG | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA4 | HSPA5 | IDO1 | IFNA1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MDM2 | MET | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SLTM | SMAD4 | SOD1 | SQSTM1 | SRC | STAT1 | STAT3 | STAT5A | TAK1 | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1